E-LIB Suche - Ergebnisse für: Blauvelt, A

1

Deucravacitinib Long-Term Efficacy in Week 16 Placebo Cross..:

Lebwohl, Mark ; Warren, Richard B. ; Imafuku, Shinichi...
SKIN The Journal of Cutaneous Medicine. 8 (2024) 2 - p. s365 , 2024

Link: https://doi.org/10.25251..

2

Lebrikizumab Provides Rapid Clinical Responses Across All E..:

Simpson, Eric L. ; de Bruin-Weller, Marjolein ; Hong, H. Chih-ho...
Dermatology and Therapy. 14 (2024) 5 - p. 1145-1160 , 2024

Link: https://doi.org/10.1007/..

3

Deucravacitinib onset of action and maintenance of response..:

Korman, Neil J. ; Warren, Richard B. ; Bagel, Jerry...
Journal of Dermatological Treatment. 35 (2024) 1 - p. , 2024

Link: https://doi.org/10.1080/..

4

Roflumilast foam 0.3% for adolescent and adult patients wit..:

Blauvelt, Andrew ; Draelos, Zoe D. ; Stein Gold, Linda...
Journal of the American Academy of Dermatology. 90 (2024) 5 - p. 986-993 , 2024

Link: https://doi.org/10.1016/..

5

505 - Once-daily roflumilast cream 0.15% for atopic dermati..:

Eichenfield, Lawrence F ; Boguniewicz, Mark ; Simpson, Eric L...
British Journal of Dermatology. 190 (2024) Supplement_2 - p. ii10-ii11 , 2024

Link: https://doi.org/10.1093/..

6

Residual Lesional Gene Expression in Psoriasis Patients wit..:

Blauvelt, Andrew ; Gordon, Kenneth B. ; Langley, Richard G....
Journal of Investigative Dermatology. , 2024

Link: https://doi.org/10.1016/..

7

Bimekizumab Continuous Maintenance of Eesponse at Every Vis..:

Blauvelt, Andrew ; Conrad, Curdin ; Costanzo, Antonio...
SKIN The Journal of Cutaneous Medicine. 8 (2024) 1 - p. s303 , 2024

Link: https://doi.org/10.25251..

8

Safety and Tolerability of Tirbanibulin Ointment 1% Treatme..:

Bhatia, Neal ; Lain, Edward ; Jarell, Abel...
JAAD International. , 2024

Link: https://doi.org/10.1016/..

9

A randomized, double-blinded, phase 2 trial of EDP1815, an ..:

Ehst, Benjamin D. ; Strober, Bruce ; Blauvelt, Andrew...
Frontiers in Medicine. 11 (2024) - p. , 2024

Link: https://doi.org/10.3389/..

10

Orismilast in moderate-to-severe psoriasis: Efficacy and sa..:

Warren, Richard B. ; French, Lars E. ; Blauvelt, Andrew...
Journal of the American Academy of Dermatology. 90 (2024) 3 - p. 494-503 , 2024

Link: https://doi.org/10.1016/..

11

Efficacy of Deucravacitinib, an Oral, Selective, Allosteric..:

Blauvelt, Andrew ; Sofen, Howard ; Lambert, Jo...
SKIN The Journal of Cutaneous Medicine. 8 (2024) 4 - p. s405 , 2024

Link: https://doi.org/10.25251..

12

650 - Stability of long-term therapeutic responses to tralo..:

Blauvelt, Andrew ; Chih-ho Hong, H ; Peris, Ketty...
British Journal of Dermatology. 191 (2024) Supplement_2 - p. , 2024

Link: https://doi.org/10.1093/..

13

551 - Continuous tralokinumab treatment over 4 years in adu..:

Blauvelt, Andrew ; Langley, Richard G ; Peris, Ketty...
British Journal of Dermatology. 190 (2024) Supplement_2 - p. ii48-ii49 , 2024

Link: https://doi.org/10.1093/..

14

721 - Efficacy and safety of povorcitinib for extensive vit..:

Pandya, Amit G ; Ezzedine, Khaled ; Passeron, Thierry...
British Journal of Dermatology. 191 (2024) Supplement_2 - p. , 2024

Link: https://doi.org/10.1093/..

15

Guselkumab Reduces Disease- and Mechanism-Related Biomarker..:

Blauvelt, Andrew ; Langley, Richard G. ; Branigan, Patrick J....
JID Innovations. 4 (2024) 5 - p. 100287 , 2024

Link: https://doi.org/10.1016/..